0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.01%IV-433.33%PremiumDec 20, 2024Expiry Date16.25Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma0.23Leverage Ratio0.0000Theta0.0000Rho-0.23Eff Leverage0.0000Vega
Accolade Stock Discussion
Accolade Announces Results for Fiscal Second Quarter 2025
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positiv...
• $Cytokinetics (CYTK.US)$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng (XPEV.US)$ +3.4% (June deliveries)
• $NIO Inc (NIO.US)$ +2.9% (June deliveries)
• $Bitfarms (BITF.US)$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade (ACCD.US)$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals (BCRX.US)$ +2.6% (presents new data demonstrating...
No comment yet